0001104659-24-038705.txt : 20240326 0001104659-24-038705.hdr.sgml : 20240326 20240326073329 ACCESSION NUMBER: 0001104659-24-038705 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240321 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240326 DATE AS OF CHANGE: 20240326 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 24780900 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 8-K 1 tm249769d1_8k.htm FORM 8-K
false 0001737953 0001737953 2024-03-21 2024-03-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  March 21, 2024

 

 

 

REPLIMUNE GROUP, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38596   82-2082553
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification Number)

 

500 Unicorn Park Drive

Suite 303

Woburn, MA 01801

(Address of principal executive offices, including Zip Code)

 

Registrant’s telephone number, including area code: (781) 222-9600

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

   Name of each exchange on which registered
Common Stock, par value $0.001 per share   REPL   The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On March 26, 2024, Replimune Group, Inc. (the “Company”) issued a press release announcing that Dr. Sushil Patel, the Company’s current chief strategy officer, has been appointed as the Company’s chief executive officer, effective as of April 1, 2024 (the “Effective Date”). In connection with Dr. Patel’s promotion to the Company’s chief executive officer, effective as of the Effective Date, (i) Dr. Patel has been appointed to join the Company’s Board of Directors (the “Board”) to serve as a Class III director, (ii) Philip Astley-Sparke, the Company’s current chief executive officer, will transition to the role of executive chairman of the Board and (iii) Dieter Weinand, the Company’s current chair of the Board, will transition into the newly created role of the lead independent director of the Board (the foregoing, collectively, the “CEO Transition”).

 

In addition to the CEO Transition, the Company announced certain other executive leadership transitions. Specifically, (i) Dr. Robert Coffin, who serves as a member of the Board and is the Company’s current president and chief research & development officer, will transition to an advisory role as founder and chief scientist, effective April 1, 2024, (ii) Dr. Colin Love, the Company’s current chief operating officer, will retire from the Company, effective May 31, 2024, (iii) Dr. Pamela Esposito, the Company’s current chief business officer, and Tanya Lewis, the Company’s current chief development operations officer, will leave their executive positions and plan to continue to lend their functional expertise in an advisory capacity and (v) Paul Bullock, the Company’s current senior vice president, operations and Framingham site head, is being promoted to the Company’s chief manufacturing officer effective April 1, 2024 (the foregoing, collectively, the “Executive Leadership Transitions” and, together with the CEO Transition, the “Transitions”).

 

In connection with the Transitions, the Company, or its wholly owned subsidiary, Replimune, Inc. (“Replimune”), entered into various agreements, certain of which are described below in accordance with clauses (c), (d) and (e) of Item 5.02 of Form 8-K.

 

Patel Second Amended and Restated Employment Agreement

 

On March 25, 2024 Dr. Patel entered into a second amended and restated employment agreement (the “Patel Second A&R Agreement”) with Replimune, which amended and restated the previous amended and restated employment agreement, dated, May 3, 2021, between Replimune and Dr. Patel, as amended further as of December 30, 2022. Under the Patel Second A&R Agreement, Dr. Patel is entitled to an initial annual base salary of $600,000 and is eligible to receive an annual discretionary performance bonus based on a target percentage of annual base salary, which target percentage is initially 60%. Each of Dr. Patel’s annual base salary and discretionary bonus may be adjusted by the compensation committee of the Board (the “Compensation Committee”). The Patel Second A&R Agreement also provides for customary terms of benefits afforded to Dr. Patel, including eligibility to participate in various group insurance plans (subject to the terms thereof), reimbursement for necessary and reasonable travel and other business expenses, and paid time off. Furthermore, Dr. Patel is eligible for grants under the Replimune Group, Inc. 2018 Omnibus Incentive Compensation Plan, as it may be amended from time to time, or any successor plan (the “Plan”), as determined by the Compensation Committee.

 

Consistent with Dr. Patel’s existing agreement, the Patel Second A&R Agreement further provides that in the event Dr. Patel’s employment is terminated by Replimune without “cause,” or by Dr. Patel for “good reason,” each, as defined in the Patel Second A&R Agreement, and subject to customary conditions, including Dr. Patel’s delivery of an effective separation agreement and general release, (a) Dr. Patel is entitled to receive an amount equal to Dr. Patel’s annual base salary, with payment made in installments over a 12-month period following the termination date in accordance with Replimune’s normal payroll practices, and (b) Replimune will pay on Dr. Patel’s behalf the COBRA premiums for continued health care coverage under its group health plans for Dr. Patel and Dr. Patel’s eligible dependents (“COBRA Payments”) for the period from the termination date until the earlier of (i) the end of the 12-month period following the termination date, (ii) the date Dr. Patel becomes eligible for group health insurance coverage through a subsequent employer, or (iii) the date Dr. Patel ceases to be eligible for COBRA coverage for any reason.

 

 

 

 

Additionally, consistent with Dr. Patel’s existing agreement, in the event that Dr. Patel’s employment is terminated by Replimune without “cause” or by Dr. Patel for “good reason” on or within 12 months following a “change of control,” as defined in the Patel Second A&R Agreement, provided that Dr. Patel delivers an effective separation agreement and general release, in lieu of the payments described in the preceding paragraph, (a) Dr. Patel is entitled to receive an amount equal to two times the sum of Dr. Patel’s annual base salary, plus Dr. Patel’s target annual discretionary bonus for the year of termination, with payment made in installments over the 24-month period following the termination date in accordance with the Replimune’s normal payroll practices, and (b) Replimune will pay on Dr. Patel’s behalf the COBRA Payments for the period from the termination date until the earlier of (i) the end of the 24-month period following the termination date, (ii) the date Dr. Patel becomes eligible for group health insurance coverage through a subsequent employer, or (iii) the date Dr. Patel ceases to be eligible for COBRA coverage for any reason.

 

Further, the Patel Second A&R Agreement provides that, in the event that Dr. Patel becomes entitled to receive payments that constitute “excess parachute payments” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended, the aggregate present value of such payments will be reduced only if such reduction will provide Dr. Patel with a greater net after-tax benefit than would no reduction.

 

Pursuant to the Patel Second A&R Agreement, Dr. Patel is subject to customary non-competition and non-solicitation covenants during the term of Dr. Patel’s employment and for a period of one year thereafter. Dr. Patel is also subject to customary confidentiality restrictions.

 

The Patel Second A&R Agreement is effective as of the Effective Date.

 

Dr. Patel, age 53, joined the Company’s management team as chief commercial officer in May 2021 and subsequently transitioned to the Company’s chief strategy officer in December 2022. From April 2018 until joining the Company, Dr. Patel served as vice president, franchise head for lung, skin, tumor agnostic, and rare cancers at Genentech, Inc., and previously held various positions of increasing responsibility at Genentech, Inc. since 2002, including global launch lead and lifecycle leader for Tecentriq in lung cancer. From 1999 to 2002, Dr. Patel was Senior Consultant at Front Line Strategic Management Consulting. Prior to this, Dr. Patel served as a senior research executive at IMS Health in the Pharma Strategy Group from 1996 to 1999 and clinical research scientist at the Central Public Health Laboratory from 1993 to 1996. Currently, Dr. Patel sits on the board of Revolution Medicines, Inc. Dr. Patel obtained a Ph.D. in Molecular Biology from the University of London in 1999, a M.S. in Biotechnology from the Imperial College London in 1993, and a B.S. in Microbiology and Microbial Technology from the University of Warwick in 1992.

 

There are no family relationships between Dr. Patel and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer of the Company within the meaning of Item 401(d) of Regulation S-K under the Securities Act (“Regulation S-K”). Since the beginning of the Company’s last fiscal year, the Company has not engaged in any transaction in which Dr. Patel had a direct or indirect material interest within the meaning of Item 404(a) of Regulation S-K.

 

Astley-Sparke Second Amended and Restated Employment Agreement

 

On March 25, 2024 Mr. Astley-Sparke entered into a second amended and restated employment agreement (the “Astley-Sparke Second A&R Agreement”) with Replimune, which amended and restated the previous amended and restated employment agreement, dated, November 2, 2021, between Replimune and Mr. Astley Sparke. Under the Astley-Sparke Second A&R Agreement, Mr. Astley-Sparke agreed to devote on average 40% of Mr. Astley Sparke’s working hours per week (and in any event, no less than 20 hours per week) to Replimune and, as consideration therefor, is entitled to an initial annual base salary of $268,686 and is eligible to receive an annual discretionary performance bonus based on a target percentage of annual base salary, which such target percentage is 60%. Each of Mr. Astley-Sparke’s annual base salary and discretionary bonus may be adjusted by the Compensation Committee. The Astley-Sparke Second A&R Agreement also provides for customary terms of benefits afforded to Mr. Astley-Sparke, including eligibility to participate in various group insurance plans (subject to the terms thereof), reimbursement for necessary and reasonable travel and other business expenses, and paid time off. Furthermore, Mr. Astley-Sparke may be eligible for grants under the Plan, as determined by the Compensation Committee.

 

Consistent with the terms of Mr. Astley-Sparke’s existing agreement, the Astley-Sparke Second A&R Agreement further provides that in the event Mr. Astley-Sparke’s employment is terminated by Replimune without “cause,” or by Mr. Astley-Sparke for “good reason,” each, as defined in the Astley-Sparke Second A&R Agreement, and subject to customary conditions, including Mr. Astley-Sparke’s delivery of an effective separation agreement and general release, (a) Mr. Astley-Sparke is entitled to receive an amount equal to Mr. Astley-Sparke’s annual base salary, with payment made in installments over a 12-month period following the termination date in accordance with Replimune’s normal payroll practices, and (b) Replimune will pay on Mr. Astley-Sparke’s behalf the COBRA Payments for the period from Mr. Astley-Sparke’s termination date until the earlier of (i) the end of the 12-month period following the termination date, (ii) the date Mr. Astley-Sparke becomes eligible for another employer’s group health insurance coverage, or (iii) the date Mr. Astley-Sparke ceases to be eligible for COBRA coverage for any reason.

 

 

 

 

Additionally, consistent with Mr. Astley-Spark’s existing agreement, in the event that Mr. Astley-Sparke’s employment is terminated by Replimune without “cause” or by Mr. Astley-Sparke for “good reason” on or within 12 months following a “change of control,” as defined in the Astley-Sparke Second A&R Agreement, provided that Mr. Astley-Sparke delivers an effective separation agreement and general release, in lieu of the payments described in the preceding paragraph, (a) Mr. Astley-Sparke is entitled to receive an amount equal to two times the sum of Mr. Astley-Sparke’s annual base salary, plus Mr. Astley-Sparke’s target annual discretionary bonus for the year of termination, with payment made in installments over the 24-month period following the termination date in accordance with Replimune’s normal payroll practices, and (b) Replimune will pay the COBRA Payments for the period from the termination date until the earlier of (i) the end of the 24-month period following the termination date, (ii) the date Mr. Astley-Sparke becomes eligible for another employer’s group health insurance coverage, or (iii) the date Mr. Astley-Sparke ceases to be eligible for COBRA coverage for any reason.

 

Further, the Astley-Sparke Second A&R Agreement provides that, in the event that Mr. Astley-Sparke becomes entitled to receive payments that constitute “excess parachute payments” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended, the aggregate present value of such payments will be reduced only if such reduction will provide Mr. Astley-Sparke with a greater net after-tax benefit than would no reduction.

 

Pursuant to the Astley-Sparke Second A&R Agreement, Mr. Astley-Sparke is subject to customary non-competition and non-solicitation covenants during the term of Mr. Astley-Sparke’s employment and for a period of one year thereafter. Mr. Astley-Sparke is also subject to customary confidentiality restrictions.

 

The Astley-Sparke Second A&R Agreement is effective as of the Effective Date.

 

Item 8.01Other Events.

 

The disclosure in Item 5.02 in respect of the Executive Leadership Transitions is incorporated by reference in this Item 8.01.

 

Item 9.01Financial Statements and Exhibits.

 

Exhibit No.   Description
     
99.1   News Release dated March 26, 2024
104   Cover page interactive data file (formatted as Inline XBRL)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  REPLIMUNE GROUP, INC.
     
Date: March 26, 2024 By: /s/ Philip Astley-Sparke
    Philip Astley-Sparke
    Chief Executive Officer

 

 

 EX-99.1 2 tm249769d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

 

Philip Astley-Sparke to transition from current role of CEO to Executive Chairman

 

Planned leadership changes position the company for commercialization

 

Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024

 

Woburn, Mass., March 26, 2024 – Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company’s preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma.

 

Sushil Patel, Ph.D., will succeed Philip Astley-Sparke as CEO effective April 1, 2024. Mr. Astley-Sparke will transition from his current role as CEO to Executive Chairman of the Board of Directors. Mr. Patel joined Replimune three years ago initially as Chief Commercial Officer and served most recently as Chief Strategy Officer. He has more than 20 years of experience in the biotech industry including pre- and post-launch commercialization strategy and execution in both U.S. and global markets. He has been involved in more than eight product launches in various roles of increasing responsibility across marketing, sales, and franchise management. Prior to joining Replimune, Mr. Patel served as franchise head for lung, skin and rare cancers at Genentech.

 

“Replimune is preparing to bring its first oncolytic immunotherapy to patients, and I am incredibly proud to be able to lead the company through this next phase of growth as we transition to a commercial stage company,” said Sushil Patel. “In the near term, we will be laser focused on delivering on our strategic priorities, including the anti-PD1 failed melanoma data and subsequent biologics license application submission, as well as launching our confirmatory trial in melanoma.”

 

Additional changes include:

 

·Robert Coffin, Ph.D., Founder, President and Chief Research & Development Officer will move to an advisory role as Founder and Chief Scientist and will continue to serve on the Board of Directors.
·Paul Bullock is being appointed Chief Manufacturing Officer and will assume oversight of manufacturing and lead operations in Framingham and Milton Park in the United Kingdom, following the retirement of Colin Love, Ph.D., Chief Operations Officer, and co-founder, who established our manufacturing operations.
·Pamela Esposito, Ph.D., Chief Business Officer, and Tanya Lewis, Chief Development Operations Officer, will leave their executive positions and plan to continue to lend their functional expertise in an advisory capacity.

 

 

 

 

“In 2015, Philip and I set out on a journey to develop a new class of oncolytic immunotherapies,” said Robert Coffin, Ph.D., Founder, President and Chief Research & Development Officer of Replimune. “As we now look towards submitting our first BLA and to future commercialization, the time is right to transition from the team that founded the company to the one that will take us through a potential launch and beyond.”

 

Philip Astley-Sparke, CEO of Replimune continued, “Rob and I are very grateful for the invaluable contributions made by Colin Love, who established our state-of-the-art manufacturing capability, Pamela Esposito for driving our financing efforts and establishing our industry collaborations and to Tanya Lewis for scaling our operations. We all remain committed to supporting the company going forward and are confident that under Sushil’s leadership, Replimune will be well positioned to realize the promise of oncolytic immunotherapy across a broad range of indications in skin cancer and beyond.”

 

About Replimune

 

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

 

Forward Looking Statements

 

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about the design and advancement of our clinical trials, the timing and sufficiency of our clinical trial outcomes to support potential approval of any of our product candidates, our goals to develop and commercialize our product candidates, patient enrollments in our existing and planned clinical trials and the timing thereof, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the coronavirus as a global pandemic and related public health issues and the Russian-Ukrainian and Israel-Hamas political and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.  

 

Investor Inquiries

 

Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com

 

Media Inquiries

 

Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com

 

 

 

 EX-101.SCH 3 repl-20240321.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 repl-20240321_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 repl-20240321_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 21, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 21, 2024
Entity File Number 001-38596
Entity Registrant Name REPLIMUNE GROUP, INC.
Entity Central Index Key 0001737953
Entity Tax Identification Number 82-2082553
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 500 Unicorn Park Drive
Entity Address, Address Line Two Suite 303
Entity Address, City or Town Woburn
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01801
City Area Code 781
Local Phone Number 222-9600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol REPL
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://replimune.com/role/Cover Cover Cover 1 false false All Reports Book All Reports repl-20240321.xsd repl-20240321_lab.xml repl-20240321_pre.xml tm249769d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm249769d1_8k.htm": { "nsprefix": "repl", "nsuri": "http://replimune.com/20240321", "dts": { "schema": { "local": [ "repl-20240321.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "repl-20240321_lab.xml" ] }, "presentationLink": { "local": [ "repl-20240321_pre.xml" ] }, "inline": { "local": [ "tm249769d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://replimune.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm249769d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm249769d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://replimune.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-038705-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-038705-xbrl.zip M4$L#!!0 ( "T\>EA"HL&@*@, .8+ 1 ],_T'U*V,[CLLM)# 42B=#*$Q2*.6E(]N;H$&6C"23P-=7 M\B4W)R%)VSQ)N^>4[-0L!"'A$V:%FW/?NT=]9N M6^CD^.,'I'_-3[:-+@C0J('.>6BW69\?H>\XA@;Z!@P$5EP3["GL$KE6*TVJA6_]>A71(9C\@X^W1WNC[KD?@#L(.U@_R'\B9^O(;B. MWAZZ.Y>_GD8J_K(?].A>\!JJ\[?;NS:Y>8";@_AK]^ME'K(IPT>(,=*7P63+ M,O45Y0U]AXN!6Z_5//?^JM/+<%8.;(PH84^+X-[AX:&;>4MH!3D*!"VE?=>X M RQAK*R]9 6>,*DP"V?PD1H3IL&[;NZ<@9*%T+T<2DIH!',X":$SX"^N=FA\ MW2^!J;0'&"=CTGJO"8FQ)0G3/C@W:9.ZX(3B%'SIY9!9ZII;$,%[WC.N'P4(D:EGY_1]Y:G\QXS MV\NMFB#D*5/B=9-&F*:4F^UN8_+Y7^\B2GQ^">8?P;9AM^B":O!%+=!TC>?L@7^/;O"&G*&?"","9UQ\C[YANE5;^%5"B4 SOGFF)".R MH-CQ&?K[T?1XA<;C ?5^(RSFXNO]O*KW,T[/)Y/7U]8CQ%_S*Q5-Z%/'- ML H7&+'T;)GHZR4NUM*7$7H""FEY -LUVFCKC)HXMKL'1$)CR_9^UR;T9[LR^^.R/Z'!M3CG3=A MR3-,WV6^'NG<]@UYWQ$_Q+D_TG*<)^\[TK7(_XOMK&WYS8?7?ERIVG@M/S4L MDETF)S 2:Y.JBHX1.-]#/C&4=5>U\ZA1+U6C.1?MMJN9,:\S)='1FK],8I+( MNJP8Q@"]ZZ&_T[8Y%UC%04 SQ"$X6]2#4!7EB:,+QK:8WI-G+KKP M:)SPMVUW\ M5.)@$3(=#J0H#T,JSA-)M=L0/0RUE*[I :R:W!BRH(BQ>P-9*>0HU_N'Y)+% M@Q"I='X ,6S:\2A% <+1=-:'AE3[!.,J22-,"R]70-4#S-0)I[N9KM9$6%I7%OB MB@W(G&;"+ ^"!<"4R4 A0TJ'"J&7GM=W"5BF'F($FV/*W!)@-]FDH*D)B 2K M,8"&@S9_IM0+$3,Y,@E,YRPFNY_)'FQ72^>6"FQW60&$ >$3K=#@" 9A)I1/D&:LXB+9UY[W&'&MW( W,]X M#*]0>J+<0C6H"4VT.D," FR(3P"S1NB'XID4Q-5[/'D%2-7@A;B+.)8'*BW_ MN4X8.0;;;]6ZI:O#;I,IBS @DF!W #^E\H/^@%0,NF6A0#-]0U.G_J&9#H5F M&C0TT_= LWSE@4!S\H:FGOB'YF0H-"=!0W/R+FADQWL=:V;RXZU8\E?;P]F@ MT@LR;:M68 ZR\'!I>>N#106H]8P*\8E)OK"Z%7>"OR0L@I?,D-P+,(!I*S6& M-CQT[ ;[^*D6Q#K.ZUA3+,I[OR1:YF>4:9JT#S&%)CQ(FL9Z!Y="[1.).YYF MF/X[>>X\$;>+O>!A-6R%I*$,#Q6;O3Y@BA@D@WR<6)>XJAL:UE?)C')WKP!; M;!U> :X5!@&!S5'[%>#BZDDABY#N<[3U7B582*U M#]^U,F;+2OO\MB>&P1TKGJY MTZ;N<:LHB-[O($V2R%ZHBT"=;"Q)M MY?RX/YZNEDE&;2>7;8FS.0DP5\U(1GD0; "F3!;R,L0?T/'TKZN_(1WEN/MO M^%)@E3QVL=^L. 6R3UE5KB#HL*@YL$B"0 'V9=)PPU$I18761W:JAEE+FN;Q0&T>DV1ZTO?Z.O/0WYE[OH49HBP L)=IGKH=]FTAS^ZYH@$.@P MUCHI*:5(:WV\D'"8LM;]BX"UMT7 NF<1L YQ$; >N@A8>UL$Z-T6*4+DN'2[ MHLD: \D).]6NH>BP;/)AD0:%"NP/'#.J$'2(<9W1,D]QIM+SBTV^_ROYP=)* M0.8J89A%":95>D3; M%?'^$&>T##1?@=.C#X.A829;.!5A.I=A%7A(=>GZ4GKQ ,9OA-*?&7]E"X)3 MSDA<7$NQW2GJUKM]8J;'=O.A&4 T"ZR1U2+K.)WA\ &0G+' MKVMWFC;>VK9J V*FTR#T#G>9\^.P-BZB/+UBF1'U>Q')"_F",UQZ ]L+R5V_ M5-EEVGR;TJ8-"*%.@^#[DU6,2A6#-5/>4L:(F5QJK7G'4^*&RGWBF);%=NZ8 M2A(0'C9?'1ED!-):+RPL-IC2S]LT822%)R)#Y98%J\4F"PU)0"S8? $LY%*D MM5Y8N-P0L9;3VT^"OV:/97Y6L&V VBT;G9:;C%BE ;'2Y0]@1H>@(D:GU/4# MS^Z04+S(L@BWU")UC UHUF"FI0L)&,AUCRYS@.1BO29 MS:B>W!Y>XC5$CE?&%H/&PKBF"((1T!:T+*[_5H"?W'G;%4VB*\HQ?)6EH7&< M,:]MSTB6=Q $1$#;%90B+Q>B7.FE_S]C]B2VSUFTOQ,\(D0]9956HU7?];>! MT6Z9>5.3FC0-"@V(L[?X!0@\5(%J=7RHS5@^+^:IA\95-C<>/2T>L3R M]LL M53.H- 9?!>\,>@'5 2C6K2G\[/TD 60 MQ)_W]^2!"/7>P9+LLL]R1T\=9Q@#8EV?O0UNCGDRUQL8!(1O=0N=ZJ6H7@%: MJ6?$RBK0[ZH2E-=B^_WR^J9K^4ENUIOD7RN<$KGEOU!+ P04 " M/'I8 MRX#$]E8' #75P %0 ')E<&PM,C R-# S,C%?<')E+GAM;,V<77/:.!2& M[W=F_X.7O28$Z'XD3;:3T-!AFC;9D+:[>],1M@!-9(F1Y #_?B4;4SXL^>3& M)[E(B'GU\3['EGULR1?O5BF/GJG23(K+5O?DM!51$C$:M M2!LB$L*EH).:VR"'C5$4#F2XX-=1^431\'OUVTNM.HG8;4.]7*A*IOCR,MO7. MC5GH\TYGN5R>"/E,EE(]Z9-8IK *QX:83&]K.UV=;GZ*XA>Z6FW\\^GVW$\IREI,^&XQ;15EG*U5)7KGIV= M=?)O2^F1:':N\^[=RIB8/.RUS41>A?NO7PTO%-54F-SKK=VP5X2N MC-V?:%)6Y-H'=\TPX]2;W:4;M=V^E:6V,?NQ4&YZ4O:%RWBO>>YB( ^\EOMS M3EK3^&0FGSL)999XK^\^.!#]'(+]YWO>T-5$&T5B4];$R83RO/[O5G,@Z330 MJY+$HZVQNE/[BL,^[4;M2L615 E5EG59%U'Q7JR.=\V-HK,@RE;4CN>,;\,\ M53+UT=F0D)Z.[H*R331#\\JVG[@^##F95>,\D !Y=C& 5KK!(OJ>ZEBQA>-2 M W9/">3;0^5;X:UAS.6Q\T!GS/77=<6=<*G;&!X7/$6 X/N8(T70+5($KH3( M"'^@"ZEJP.\K@;S?8/*N\H:$^>^,*$,57T-('XF!L'_#A.UQB,3[41&AF>,# M 7ZL!A+_'?7"P^,1"?EX3CEW21P1H+V\2@_$_@W#L*'EHKB.EJ MM3E,SO=2&\+_8XNZ*\EJ/90Y8N(:,MKT#<8B[NZFA6\JT8$$RAJZ8'7S236WD-_ MYVOP##:48?701L,8OREF; \&,DTSL;E'XWDJYI%"\:*D?T%[#:,>2\YB9IB8 M?;)7B(H17LVY2@>%C)+L^8TU3/A>41=I:B^[\WE<;JF!NIM.?2-O2 \ECI+K MU1O%)3_2.J/JI?PK2D&C@)+V04TW/<[0.+/#WKK;FSRZ%3.>4>9(!66-DO+Y M3#7,]K-\5,2MUANOTXGD_N4AE4(H890$+V"M8R"!@D7)["KM((T) M-ZMX3L2,^FU$R/I\I)+;%W'![1-U-.)L1 M_TJR8 'P.AM,X@&K3:_?RY?\N'7<*LW[,;0?JK%[I%#@.$LD0_::1ITES-"D MZ-*0"2)BFU)MU[5YLO/Z4M X*RA!)I&N;W_C7+^4*10YXK-#CSV( MN*\$%#SB0\2P6:3Y:8:Z/K-G^IX8LNEAB+^O!)0_X@/%L%FT^?-J8$\\,QE^ M9GX@A-)&G I;:0T%\C@EG%]GF@FJ@V/+@1 *&7'.:Z4U%,@W*54S.ZA]4')I MYINUG2'8G@)0Z(@S6X-6<>"O?JPC+]:_!5MHTD-]*6@44-)5J&F<<^O. M2O[@J75/!^6-F)A6&<-9,Y5-.(N'7)+@=?F>#,H7,0NML(6"]YJ()Y4M3+R^ M5S*FU#T^T=NC#9 0 2N A@0Q/WT1"IS;!3)-W6(B&3^-Y]:TOLM,_OY2V[_@ M38-@.6AH,!=Q HPC707I'PN]:'*]?J!3JMPTA4>Z,M>VH:?P11&@.#0^J&\4 M F.H"--%Y\C7K=W@WE!;?.-^N;>PVBW_ U!+ P04 " M/'I8@9VT7!H? M !JL $0 '1M,C0Y-S8Y9#%?.&LN:'1M[3UI4^-(LM_U*^JQVSL081L? M8,YF XSI\3378)CNMU^(LE2V-2U+:I4$]OSZS:PJ799D;+"!WNF)W0:L.C*S M\LY4^?#?XY%%'IC'3?/SEN-OJ='[Y]Y%V./1A& RU M^<>UH>^[^YN;CX^/E<=&Q?$&F[6]O;W-,8Y9DX/VQ[GCZM5J;?/KQ7E7'[(1 M+9LV]ZFMLVB29=K?BM?'I]'0GF>9J:'X2;A)8S.S-#PUX@G)P+B?/SX>NNE[U.9]QQM1 M'XX05]HN5^OE>C.Q2)DS/;40_%T9. ]/KK-;;M3"=3*'D\84'_$P[:JC7IM#86+4>-( M(_C?H6_Z%CLZW)0_M<,1\RG!%V ^?%QK.;;/;+]\.W&!UKK\Z^.:S\;^ MII# 39BU*9<\_+]RF9R9S#+V29?Y!^22CM@^&1OC ](Y%;_<5^NM^[ONA_KI MI^/C:_B!\)-R><[)C;-[Q.L^A=Q]B-S\ZVR=19.>,7M[[YX!6P'T\+_C$;,- M^+]_9M'!?9]:G"VPTG%BI;8-IS!IP5(>M3JVP<:?V>2^"DILI[&SM[T F9HG M0./3^]J]T@=R??AH@27J]]TA]1B_K]\+[2?7X.*S!98Y14BNU5*-#$!%:_<< M8T*X/['8Q[4^,-T^J55=G]R:(QAQR1[)C3.B=DE^4(+]/;./O&V8#^$TP^2N M12?[Q'9LAL_,\3[R*?. ^<4?IF$P&R4!_X)1E\$(UM$EEX_]&]04Q_RJCQQ2 MKC;*(#[$!B1A;6;NIPY^C9C&QS5S_%!N-/;6C@0;'&ZFEGWV1KE\D=APJ[IV M%'-)WJZ;26P1!E!SS /#R[AXCLITGPLK"; 08?KVAT)3HJ250Q&IC+FQIA[[ MH! ^KG%SY%H,E8#:)K6RW(H[@:=V@D'BP/<5Y@*)*+A#2,3(@@,GW_%/JLZ,8^G"=^-GT M+&":@CGADRF0DKN'GRGRI4@:V*:D)XC5-!%'C/+ 8T=*_/9A2+A4^"BU/JZ5 MO[B4Y*+U%?)BS#,WB-7%]"8@VW!P&8+B3,'LU'>\^.G"N$^#E[-F8L=39CLC MTWYBSR?I,;UISK+AXR3ZTV14HA=+FA1YI>T.-V'ND:9IA^ZB.O6 C*@W,.U] M@D.K!P39KDPM

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tm249769d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001737953 2024-03-21 2024-03-21 iso4217:USD shares iso4217:USD shares false 0001737953 8-K 2024-03-21 REPLIMUNE GROUP, INC. DE 001-38596 82-2082553 500 Unicorn Park Drive Suite 303 Woburn MA 01801 781 222-9600 false false false false Common Stock, par value $0.001 per share REPL NASDAQ true true